Federal Register Notice: FDA is making available additional draft and revised draft product-specific bioequivalence (BE) recommendations to provide guidance on the design of BE studies to support ANDAs. Products include carbamazepine, cholestyramine, fingolimod, and methylphenidate HCl. To view this notice, click here.
